SAMSUNG BIOLOGICS CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7,70,000 KRW | -1.28% |
|
-1.41% | +1.32% |
| 25/04 | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
| 25/04 | Samsung Biologics Posts Higher Q1 Profit, Sales | MT |
| Sales 2024 * | 4,263B 3.1B 258B | Sales 2025 * | 4,915B 3.57B 298B | Capitalization | 54,804B 39.84B 3,320B |
|---|---|---|---|---|---|
| Net income 2024 * | 976B 710M 59.12B | Net income 2025 * | 1,177B 856M 71.3B | EV / Sales 2024 * | 12.4 x |
| Net cash position 2024 * | 2,085B 1.52B 126B | Net cash position 2025 * | 2,961B 2.15B 179B | EV / Sales 2025 * | 10.5 x |
| P/E ratio 2024 * |
56.2
x | P/E ratio 2025 * |
47.8
x | Employees | 4,284 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 25.25% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -1.28% | ||
| 1 week | -1.41% | ||
| Current month | -7.34% | ||
| 1 month | -7.00% | ||
| 3 months | -0.39% | ||
| 6 months | +5.62% | ||
| Current year | +1.32% |
1 week
769 000.00
805 000.00
1 month
769 000.00848 000.00
Current year
739 000.00880 000.00
1 year
668 000.00880 000.00
3 years
668 000.001 000 000.00
5 years
241 500.001 000 000.00
10 years
125 500.001 000 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
John Chongbo Rim
CEO | Chief Executive Officer | 62 | 01/18/01 |
Doyoung Heo
DFI | Director of Finance/CFO | - | - |
Tae-Han Kim
CHM | Chairman | 66 | 21/11/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chang-Woo Lee
BRD | Director/Board Member | 70 | - |
Tae-Han Kim
CHM | Chairman | 66 | 21/11/21 |
Seok-Woo Jung
BRD | Director/Board Member | 62 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.63% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 7,70,000 | -1.28% | 82,298 |
| 25/24/25 | 7,80,000 | -1.27% | 68,732 |
| 24/24/24 | 7,90,000 | -0.13% | 48,667 |
| 23/24/23 | 7,91,000 | -1.37% | 44,112 |
| 22/24/22 | 8,02,000 | +2.69% | 59,922 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
Samsung Biologics Co Ltd is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
24/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
7,70,000
KRW
Average target price
10,32,273
KRW
Spread / Average Target
+34.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.32% | 39.82B | |
| -4.66% | 86.13B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B | |
| +2.29% | 7.72B |
- Stock Market
- Equities
- A207940 Stock
